Clinical Trials

280 enrolled

Dermatologic

Melanoma

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 2 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03919071 2026-04-13

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

58 enrolled

CNS

Astrocytoma, Glioblastoma, Glioma

NCT04439292 2026-04-13

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

LymphoidOther hematologic neoplasmPlasma cell

35 enrolled

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT07506109 2026-04-07

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

49 enrolled

Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT02693535 2026-04-02

TAPUR

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03244956 2026-03-23

MERAIODE

Phase 2 Completed

40 enrolled

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation

NCT04675710 2026-02-19

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

30 enrolled

Thyroid Carcinoma, Anaplastic

NCT02231775 2026-02-13

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

58 enrolled

Dermatologic

Melanoma

NCT04452877 2026-01-13

A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

Phase 2 Completed

40 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

52 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01972347 2025-12-16

Neo Combi

35 enrolled

Dermatologic

Fever, Melanoma

NCT04116541 2025-11-21

MegaMOST

455 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

19 enrolled

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

NCT01723202 2025-08-24

Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer

Phase 2 Completed

53 enrolled 11 charts

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT04238624 2025-07-02

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

16 enrolled

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT06978400 2025-05-18

A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer